Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy (Q45880221)

17 December 2017

title

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy (English)

1 reference

17 December 2017

1 reference

1 reference

8

1 reference

17 December 2017

Pier Mannuccio Mannucci

7

object named as

Pier M Mannucci

1 reference

17 December 2017

Marta Spreafico

1

1 reference

17 December 2017

Corrado Lodigiani

2

1 reference

17 December 2017

Y van Leeuwen

3

1 reference

17 December 2017

Denise Pizzotti

4

1 reference

17 December 2017

Lidia L Rota

5

1 reference

17 December 2017

Fr Rosendaal

6

1 reference

17 December 2017

publication date

1 September 2008

1 reference

17 December 2017

published in

Pharmacogenomics

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

9

1 reference

17 December 2017

page(s)

1237-1250

1 reference

17 December 2017

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenetics of acenocoumarol pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Acenocoumarol stabilization is delayed in CYP2C93 carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Evaluation of genetic factors for warfarin dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

10.2217/14622416.9.9.1237

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017